Moderator: Jean-François Formela, MD, Partner, Atlas Venture
Jay Bradner, MD, President, Novartis Institutes for Biomedical Research
Mark Murcko, PhD, CSO, Relay Therapeutics
Georgia Papathomas, PhD, SVP, Global Head of Data Sciences, Johnson & Johnson
Eric Perakslis, PhD, CSO, Datavant
Lee Lehman-Becker, Senior Director, Digital and Personalized Health Care Partnering, Roche
The drug development process is highly complex and has many drivers. The panel will discuss the strategic impact of AI on the entire process and the implications for health care overall. How will the combination of factors – research strategy, drug development, regulatory approvals, reimbursement and clinical effectiveness – be influenced by the implementation of AI. Panelists will discuss short and mid-term prospects and whether AI will ultimately lead to a restructuring of the pharma model to develop new therapies.
